checkAd

    DGAP-News  610  0 Kommentare Novavax Prices Public Offering of Common Stock


    DGAP-News: Novavax, Inc. /
    Novavax Prices Public Offering of Common Stock

    06.06.2014 / 03:06

    ---------------------------------------------------------------------

    GAITHERSBURG, Md., 2014-06-06 03:06 CEST (GLOBE NEWSWIRE) --
    Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
    on the discovery, development and commercialization of recombinant nanoparticle
    vaccines and adjuvants, today announced that it has priced an underwritten
    public offering of 25 million shares of common stock at a price to the public
    of $4.00 per share for gross proceeds of approximately $100 million. Novavax
    expects to receive net proceeds, after deducting the underwriting discount, of
    approximately $94 million from the offering. In connection with this offering,
    Novavax expects to grant to the underwriters a 30-day option to purchase up to
    an additional 3.75 million shares of its common stock. If the underwriters
    exercise this option in full, Novavax will have offered 28.75 million shares of
    its common stock.

    Novavax intends to use the net proceeds from the offering for general corporate
    purposes, the advancement of its clinical-stage vaccine candidates and its
    pre-clinical research programs, manufacturing and process development
    activities, capital expenditures and other strategic purposes. The offering is
    expected to close on or about June 11, 2014, subject to the satisfaction of
    customary closing conditions.

    Citigroup and JP Morgan are acting as joint book-running managers of the
    offering. Piper Jaffray & Co. will act as Lead Manager and FBR and Ladenburg
    Thalmann & Co. Inc. as Co-Managers.

    A preliminary prospectus supplement and the prospectus relating to the proposed
    offering has been filed with the SEC. The offering may be offered only by means
    of a prospectus, including a prospectus supplement, forming a part of the
    effective registration statement. This press release does not and shall not
    constitute an offer to sell or the solicitation of an offer to buy, nor will
    there be any sale of these securities in any state or jurisdiction in which
    such offer, solicitation or sale would be unlawful prior to registration or
    qualification under the securities laws of any such state or jurisdiction. When
    available, copies of the final prospectus supplement and the prospectus
    relating to the proposed offering can be obtained at the SEC's website
    http://www.sec.gov or from Citigroup and JP Morgan, Attention: Citigroup, c/o
    Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
    telephone at (800) 831-9146; or J.P. Morgan Securities LLC, c/o Broadridge
    Seite 1 von 2


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Novavax Prices Public Offering of Common Stock DGAP-News: Novavax, Inc. / Novavax Prices Public Offering of Common Stock 06.06.2014 / 03:06 --------------------------------------------------------------------- GAITHERSBURG, Md., 2014-06-06 03:06 CEST (GLOBE NEWSWIRE) -- Novavax, Inc. …

    Schreibe Deinen Kommentar

    Disclaimer